Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Share-based Compensation (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Share-based Compensation data on record, last reported at $118000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 14.49% year-over-year to $118000.0; the TTM value through Sep 2025 reached $468000.0, down 22.77%, while the annual FY2024 figure was $625000.0, 41.42% down from the prior year.
  • Share-based Compensation reached $118000.0 in Q3 2025 per CYCN's latest filing, up from $114000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.5 million in Q4 2021 and bottomed at $103000.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $942157.9, with a median of $379000.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: crashed 90.84% in 2023, then increased 18.45% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $2.5 million in 2021, then plummeted by 55.87% to $1.1 million in 2022, then plummeted by 90.84% to $103000.0 in 2023, then rose by 18.45% to $122000.0 in 2024, then dropped by 3.28% to $118000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $118000.0 in Q3 2025, $114000.0 in Q2 2025, and $114000.0 in Q1 2025.